Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/17/2025

Breakthrough Pain Management with IV Hydromorphone

Dosing Guidelines

  • The National Comprehensive Cancer Network recommends that breakthrough doses should equal 10-20% of the total 24-hour opioid requirement, calculated in morphine equivalents and converted to hydromorphone, for opioid-tolerant patients 1, 2, 3
  • For patients receiving around-the-clock opioids, the breakthrough dose can be calculated by converting their total daily dose to IV hydromorphone equivalents (using a 5:1 morphine-to-hydromorphone ratio) and providing 10-20% of that total as the rescue dose 1, 3

Reassessment and Titration Protocol

  • The National Comprehensive Cancer Network suggests that efficacy and adverse effects must be assessed every 15 minutes for IV opioids to determine subsequent dosing 1, 2
  • If pain remains unchanged or worsens after 15 minutes, administer 50-100% of the previous rescue dose (0.5-1mg additional if the initial dose was 1mg) and continue reassessing every 15 minutes 1, 2

Critical Safety Considerations

  • The National Comprehensive Cancer Network recommends prophylactically prescribing stimulant laxatives with or without stool softeners for all patients receiving opioids, as constipation is nearly universal 1, 3

Common Pitfalls to Avoid

  • The National Comprehensive Cancer Network advises against using extended-release or controlled-release formulations for breakthrough pain—only immediate-release formulations like IV hydromorphone are appropriate 2, 4
  • The National Comprehensive Cancer Network suggests not withholding adequate breakthrough dosing out of fear of overdose in opioid-tolerant patients—these patients require higher doses proportional to their baseline opioid consumption 1, 2

REFERENCES

1

adult cancer pain. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2013

2

adult cancer pain, version 3.2019, nccn clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2019

3

Hydromorphone Dosing Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025